To The East! Leo CEO On Astellas Deal And Global Ambitions
This article was originally published in PharmAsia News
The acquisition of Astellas's dermatology business for €675m ($725m) by Denmark's skin disease specialist Leo Pharma, announced Nov. 11, is as much about satisfying the company's desire to reach critical mass in certain markets, including China, as it is about reviving an aging portfolio of products.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
The European Commission has extended the indications for Janssen’s Tremfya to include psoriatic arthritis, and those for BMS’s Opdivo to include gastroesophageal cancer.